| Literature DB >> 20674470 |
Abstract
Some therapeutic monoclonal antibodies function by focusing the killing power of the immune system on particular cellular targets, a process known as antibody-dependent cell-mediated cytotoxicity (ADCC). There is considerable interest in developing small-molecule therapeutics that utilize this mechanism of action and so act as a kind of antibody surrogate. Progress and challenges in this interesting field are reviewed here.Entities:
Mesh：
Substances：
Year: 2010 PMID： 20674470 PMCID： PMC3050540 DOI： 10.1016/j.cbpa.2010.07.002
Source DB: PubMed Journal: Curr Opin Chem Biol ISSN： 1367-5931 Impact factor: 8.822